AURKB and colorectal carcinoma: However, the order of sequential combination differs to our study, where we rationally employed AZD1152 following upregulation of AURKB activity, where this inhibitor markedly sensitised cells with prior 5-FU treatment in in vitro and ex vivo models of CRC.